2024
Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review
Javaheri A, Ozcan M, Moubarak L, Smoyer K, Rossulek M, Revkin J, Groarke J, Tarasenko L, Kosiborod M. Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review. Heliyon 2024, 10: e35916. PMID: 39229539, PMCID: PMC11369438, DOI: 10.1016/j.heliyon.2024.e35916.Peer-Reviewed Original ResearchGDF-15 concentrationsGrowth differentiation factor 15Differentiation factor 15GDF-15Heart failureMultivariate analysisRenal functionComposite outcomeAdverse outcomesOptimal treatment regimensPredictors of mortalityCardiovascular-related mortalityCross-sectional studyPrognostic roleTreatment regimensClinical risk prediction modelsPoor outcomeRisk prediction modelExercise capacityEligibility criteriaPatientsPRISMA guidelinesMortalityNonfatal outcomesOutcomes
2023
A Phase 1b First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Crawford J, Calle R, Collins S, Weng Y, Lubaczewski S, Buckeridge C, Wang E, Harrington M, Tarachandani A, Rossulek M, Revkin J. A Phase 1b First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. Clinical Cancer Research 2023, 30: 489-497. PMID: 37982848, PMCID: PMC10831332, DOI: 10.1158/1078-0432.ccr-23-1631.Peer-Reviewed Original ResearchThe mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review.
Dunne R, Bonomi P, Crawford J, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review. Journal Of Clinical Oncology 2023, 41: 87-87. DOI: 10.1200/jco.2023.41.4_suppl.87.Peer-Reviewed Original ResearchPancreatic cancerPoor survivalInternational Consensus Diagnostic CriteriaRisk of cachexiaUnintentional weight lossCancer-associated cachexiaSystematic literature reviewConsensus diagnostic criteriaProgressive functional impairmentPoor prognosisColorectal cancerUnivariate analysisMortality burdenFunctional impairmentCachexiaPRISMA guidelinesDiagnostic criteriaEligibility criteriaPatientsClinical practiceRoutine assessmentMultivariate analysisSignificant associationWasting disorderCancer
2022
1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review
Bonomi P, Crawford J, Dunne R, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. 1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review. Annals Of Oncology 2022, 33: s1281. DOI: 10.1016/j.annonc.2022.07.1919.Peer-Reviewed Original Research1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy
Roeland E, Fintelmann F, Yang R, Tarasenko L, McRae T, Revkin J, Bonomi P. 1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy. Annals Of Oncology 2022, 33: s1125. DOI: 10.1016/j.annonc.2022.07.1396.Peer-Reviewed Original Research
2017
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. New England Journal Of Medicine 2017, 376: 1517-1526. PMID: 28304227, DOI: 10.1056/nejmoa1614062.Peer-Reviewed Original ResearchConceptsLDL cholesterol levelsProprotein convertase subtilisin kexin type 9Antidrug antibodiesCholesterol levelsLipoprotein cholesterolLow-density lipoprotein cholesterolSubtilisin kexin type 9Antidrug antibody formationLipid-lowering trialsCommon adverse eventsMajor cardiovascular eventsDensity lipoprotein cholesterolInjection site reactionsTime of enrollmentHumanized monoclonal antibodyCardiovascular eventsStatin therapyAdverse eventsTotal cholesterolMultinational trialTreatment periodBococizumabApolipoprotein BPatientsType 9
2007
PO23-763 EFFICACY AND SAFETY OF COMBINATION TORCETRAPIB/ATORVASTATIN VERSUS ATORVASTATIN ALONE IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Revkin J, Ose L, Marais A, Pretorius M, Viljoen J, Burgess L, Lan S, Thuren T, Shear C. PO23-763 EFFICACY AND SAFETY OF COMBINATION TORCETRAPIB/ATORVASTATIN VERSUS ATORVASTATIN ALONE IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA. Atherosclerosis Plus 2007, 8: 203. DOI: 10.1016/s1567-5688(07)71773-7.Peer-Reviewed Original Research
2005
W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease
Nissen S, Tardif J, Crowe T, Thuren T, Shear C, Revkin J. W16-P-060 Design of a study comparing torcetrapib/atorvastatin with atorvastatin alone on atheroma volume in patients with coronary heart disease. Atherosclerosis Plus 2005, 6: 116. DOI: 10.1016/s1567-5688(05)80456-8.Peer-Reviewed Original Research